Delcath Systems (DCTH) reported Thursday preliminary Q3 revenue of $11.2 million that includes $10 million in US revenue from the commercialization of Hepzato Kit, which is indicated for treating metastatic uveal melanoma.
The oncology company reported $434,000 in Q3 revenue a year earlier.
Analysts polled by Capital IQ expect Q3 revenue of $9.5 million.
The company said the $10 million in US revenue triggers a $25 million financing tranche relating to warrants issued in March 2023. Warrant holders will have 21 days to exercise their warrants to acquire common shares at a price of $6 apiece for an aggregate exercise price of up to about $25 million, the company said.
Delcath Chief Executive Gerard Michel said the additional $25 million of financing will be used to support an ongoing commercial launch and invest in new clinical trials to expand indications that the company intends to start next year.
The company is scheduled to report Q3 financial results on Nov. 8.
Delcath shares were up almost 14% in early trading Thursday.
Price: 10.83, Change: +1.32, Percent Change: +13.83
免責聲明：投資有風險，本文並非投資建議，以上內容不應被視為任何金融產品的購買或出售要約、建議或邀請，作者或其他用戶的任何相關討論、評論或帖子也不應被視為此類內容。本文僅供一般參考，不考慮您的個人投資目標、財務狀況或需求。TTM對信息的準確性和完整性不承擔任何責任或保證，投資者應自行研究並在投資前尋求專業建議。